Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Beauty Health (SKIN) Research & Development (2020 - 2026)

SkinHealth Systems has reported Research & Development over the past 6 years, most recently at $1.7 million for Q4 2025.

  • Quarterly Research & Development rose 37.56% to $1.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.6 million through Dec 2025, down 10.61% year-over-year, with the annual reading at $5.6 million for FY2025, 10.61% down from the prior year.
  • Research & Development was $1.7 million for Q4 2025 at SkinHealth Systems, down from $1.7 million in the prior quarter.
  • Over five years, Research & Development peaked at $3.0 million in Q4 2023 and troughed at $998000.0 in Q1 2025.
  • The 5-year median for Research & Development is $1.9 million (2021), against an average of $1.9 million.
  • Year-over-year, Research & Development surged 400.5% in 2021 and then plummeted 64.45% in 2025.
  • A 5-year view of Research & Development shows it stood at $1.9 million in 2021, then fell by 22.88% to $1.4 million in 2022, then soared by 110.65% to $3.0 million in 2023, then crashed by 59.88% to $1.2 million in 2024, then soared by 37.56% to $1.7 million in 2025.
  • Per Business Quant, the three most recent readings for SKIN's Research & Development are $1.7 million (Q4 2025), $1.7 million (Q3 2025), and $1.3 million (Q2 2025).